XML 34 R21.htm IDEA: XBRL DOCUMENT
v3.25.3

Segment Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Information by Segment | The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024. Schedule of Information by Segment
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Clinical and related oversight costs |  | $ | 13,424 |  |  | $ | 250,342 |  |  | $ | 40,894 |  |  | $ | 358,319 |
Preclinical research focused on development of additional novel anti-cancer compounds |  |  | 22,211 |  |  |  | 90,821 |  |  |  | 92,573 |  |  |  | 300,130 |
Compound maintenance |  |  | 7,480 |  |  |  | 9,062 |  |  |  | 60,563 |  |  |  | 18,932 |
Regulatory service costs |  |  | 7,581 |  |  |  | 11,405 |  |  |  | 8,771 |  |  |  | 14,021 |
Total research and development costs |  | $ | 50,696 |  |  | $ | 361,630 |  |  | $ | 202,801 |  |  | $ | 691,402 |
The following table presents a summary of research and development costs for the three months and nine months ended September 30, 2025 and 2024 based on the respective geographical regions where such costs were incurred.
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
United States |  | $ | 46,305 |  |  | $ | 278,808 |  |  | $ | 146,804 |  |  | $ | 427,736 |
Spain |  |  | 4,391 |  |  |  | 6,544 |  |  |  | 55,997 |  |  |  | 51,022 |
China |  |  | — |  |  |  | — |  |  |  | — |  |  |  | 2,282 |
Netherlands |  |  | — |  |  |  | 76,278 |  |  |  | — |  |  |  | 210,362 |
Total research and development costs |  | $ | 50,696 |  |  | $ | 361,630 |  |  | $ | 202,801 |  |  | $ | 691,402 |
The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs for the three months and nine months ended September 30, 2025 and 2024.
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
|  | Three Months Ended |  |  | Nine Months Ended |
|  | September 30, |  |  | September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Compensation to related parties: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash-based |  | $ | 217,416 |  |  | $ | 176,226 |  |  | $ | 449,432 |  |  | $ | 566,624 |
Stock-based |  |  | 776,611 |  |  |  | 106,827 |  |  |  | 1,144,348 |  |  |  | 340,445 |
Patent and licensing legal and filing fees and costs |  |  | 16,853 |  |  |  | 45,415 |  |  |  | 90,239 |  |  |  | 192,238 |
Other consulting and professional fees |  |  | 538,822 |  |  |  | 117,893 |  |  |  | 920,689 |  |  |  | 481,865 |
Insurance expense |  |  | 64,277 |  |  |  | 116,440 |  |  |  | 192,830 |  |  |  | 370,167 |
Other costs and expenses, net |  |  | 136,679 |  |  |  | 58,826 |  |  |  | 282,764 |  |  |  | 316,551 |
Total general and administrative costs |  | $ | 1,750,658 |  |  | $ | 621,627 |  |  | $ | 3,080,302 |  |  | $ | 2,267,890 |
The following table presents the Company’s total assets by segment at September 30, 2025 and December 31, 2024.
|  | September 30, 2025 |  |  | December 31, 2024 |
Research and development assets |  | $ | 10,412 |  |  | $ | 39,298 |
Corporate assets (primarily cash and digital assets) |  |  | 5,423,264 |  |  |  | 1,106,205 |
Total assets |  | $ | 5,433,676 |  |  | $ | 1,145,503 |

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration